sickle cell disease
EC approves Vertex’s Casgevy for sickle cell disease treatment
February 13, 2024Medical Communications Casgevy, European Commission, Haematology, Vertex pharmaceuticals, sickle cell disease
Vertex Pharmaceuticals has announced that the European Commission (EC) has granted conditional marketing authorisation to Casgevy (exagamglogene autotemcel), a CRISPR/Cas9 …
FDA halts studies for bluebird bio’s sickle cell therapy LentiGlobin
February 24, 2021Research and Development Bluebird Bio, FDA, sickle cell disease
The FDA has put bluebird bio’s LentiGlobin gene therapy programme for sickle cell disease (SCD) on clinical hold, following Suspected …
Novartis and Gates Foundation join forces on sickle cell disease research
February 17, 2021Research and Development Novartis, sickle cell disease
Novartis has entered into a grant agreement with the Bill & Melinda Gates Foundation, under which the foundation will fund …
FDA approves GBT’s Oxbryta to treat sickle cell disease
November 26, 2019Manufacturing and Production FDA, FDA Trump, Oxbryta, Sickle cell, sickle cell disease
The FDA announced yesterday that it has approved Global Blood Therapeutics’ marketing application for its haemoglobin polymerisation inhibitor Oxbryta, which …
Novartis’ Adakveo becomes first FDA-approved P-selectin inhibitor for sickle cell disease
November 18, 2019Sales and Marketing Adakve, Novartis, pharma, sickle cell disease
The FDA has chosen to award Novartis’ Adakveo (crizanlizumab) with marketing authorisation, it has emerged, as a treatment to reduce …
Novartis’ sickle cell drug reduces vaso-occlusive crises by 35% at Phase 2
October 10, 2018Research and Development Novartis, crizanlizumab, pharma, sickle cell disease
Novartis has presented new Phase 2 data for its humanised anti-P-selectin monoclonal antibody crizanlizumab in the treatment of sickle cell …
FDA gives go-ahead to first sickle cell treatment in 20 years
July 10, 2017Sales and Marketing Emmaus Medical, L-glutamine, sickle cell disease
Emmaus Medical has been handed approval for the first new treatment for sickle cell disease in two decades. The active …
Shares in Global Blood jump after positive results for trial sickle cell drug
June 13, 2016Research and Development, Sales and Marketing Global Blood Therapeutics, drug trial, sickle cell disease
Global Blood Therapeutics (Nasdaq: GBT) shares jumped to close up over 9% Friday after the company said its trial drug …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
